ZURA Stock — Zura Bio Limited Class A: Cash, EV, Pipeline

Share price

$4.46

Market cap

$427.4M

Cash

$205.1M

Enterprise value

$222.3M

Balance sheet

Cash	$205.1M
Debt	$0.0M
Net cash	$205.1M
Enterprise value	$222.3M
Basic shares	95.4M shares
Fully diluted shares	144.6M shares
Fully diluted market cap	$644.9M
Cash per share	$2.15

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ZURA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Dec 13, 2026 - Jan 24, 2027	Tibulizumab Dose A	Phase 2	Hidradenitis Suppurativa (HS)	—
Jun 12 - Jul 24	Tibulizumab	Phase 2	Systemic Sclerosis (SSc); Scleroderma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

tibulizumab

Phase 2 · Active Modality: bispecific antibody

Aliases ZB-106

Target BAFF and IL-17A

Partnerships Eli Lilly (exclusive license to develop, manufacture and commercialize tibulizumab, Apr 2023; up to $155M development milestones + $440M sales milestones)

Indications

hidradenitis suppurativa (HS) (Phase 2)
systemic sclerosis (SSc), early diffuse cutaneous (Phase 2)
polymyalgia rheumatica (PMR) (Phase 2)

Catalysts

— Q4 2026
— end of 2026
— H1 2027

Status note Lead candidate; bispecific dual-antagonist antibody (tabalumab fused with scFv from ixekizumab). TibuSHIELD (HS) and TibuSURE (SSc) are global randomized double-blind placebo-controlled Phase 2 trials.

crebankitug

Phase 1 · Active Modality: antibody

Target IL-7Rα

Status note Evaluated in Phase 1 and Phase 1b studies; company assessing potential therapeutic indications and future development strategies.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Tibulizumab Dose A
Lead indication	Hidradenitis Suppurativa (HS)
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06993610	Phase 2	Active, not recruiting	Sponsor	Zura Bio Inc	—	Hidradenitis Suppurativa (HS)	—
NCT06843239	Phase 2	Active, not recruiting	Sponsor	Zura Bio Inc	—	Systemic Sclerosis (SSc); Scleroderma	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Zura Bio Inc on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Braidwell LP	3,980,295	-8,694	0.87%	2026-08-14
ADAR1 Capital Management	1,759,295	+1,128,892	0.49%	2026-08-14
Ikarian Capital	1,218,492	+25,000	1.18%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ZURA — Zura Bio Limited Class A